Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NEO212 |
Synonyms | |
Therapy Description |
NEO212 is a conjugate of temozolomide and perillyl alcohol, which may result in decreased cell migration and invasion, inhibition of Fak/Src signaling, and cytotoxicity (PMID: 29440289, PMID: 31839810). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NEO212 | NEO212 is a conjugate of temozolomide and perillyl alcohol, which may result in decreased cell migration and invasion, inhibition of Fak/Src signaling, and cytotoxicity (PMID: 29440289, PMID: 31839810). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |